Treatment of critically ill patients with candidemia

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 2, 2008, Pages

  Mensa, José ^a   Pitart, Cristina ^a   Marco, Francesc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Candidemia; Critically ill patients; Echinocandins

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; CANDIDA; CANDIDEMIA; CHORIORETINITIS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FUNGAL COLONIZATION; HUMAN; MENINGITIS; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; PERITONITIS; PRIORITY JOURNAL; SEPSIS; SPECIES COMPARISON; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ANTIFUNGAL AGENTS; CANDIDIASIS; CRITICAL ILLNESS; ECHINOCANDINS; FUNGEMIA; HUMANS; UNITED STATES;

EID: 55649121803     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(08)70007-4     Document Type: Article

References (23)

1. Spellberg B.J., Filler S.G., and Edwards Jr. J.E. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 42 (2006) 244-251
2. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49 (2005) 3640-3645
3. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 (2006) 25-31
4. Parkins M.D., Sabuda D.M., Elsayed S., and Laupland K.B. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 60 (2007) 613-618
5. León C., Ruiz-Santana S., Saavedra P., Almirante B., Nolla-Salas J., Alvarez-Lerma F., et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34 (2006) 730-737
6. Ostrosky-Zeichner L., Sable C., Sobel J., Alexander B.D., Donowitz G., Kan V., et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26 (2007) 271-276
7. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., and Wenzel R.P. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 149 (1989) 2349-2353
8. Blumberg H.M., Jarvis W.R., Soucie J.M., Edwards J.E., Patterson J.E., Pfaller M.A., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33 (2001) 177-186
9. Shorr A.F., Lazarus D.R., Sherner J.H., Jackson W.L., Morrel M., Fraser V.J., et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 35 (2007) 1077-1083
10. Horvath L.L., George B.J., and Hospenthal D.R. Detection of fifteen species of Candida in an automated blood culture system. J Clin Microbiol 45 (2007) 3062-3064
11. George B.J., Horvath L.L., and Hospenthal D.R. Effect of inoculum size on detection of Candida growth by the BACTEC 9240 automated blood culture system using aerobic and anaerobic media. J Clin Microbiol 43 (2005) 433-435
12. Pitart C, Marco F, Mensa J. Time-to-positivity and blood anaerobic culture vials can predict Candida glabrata bloodstream infections. In: Abstracts of 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC: ASM Press; 2008, p. 628, abstract M-704.
13. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., van der Horst C.M., Edwards J.E., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331 (1994) 1325-1330
14. Anaissie E.J., Darouiche R.O., Abi-Said D., Uzun O., Mera J., Gentry L.O., et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23 (1996) 964-972
15. Rex J.H., Pappas P.G., Karchmer A.W., Sobel J., Edwards J.E., Hadley S., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 (2003) 1221-1228
16. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 (2005) 1435-1442
17. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
18. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007) 1519-1527
19. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007) 2472-2482
20. Pappas P.G., Rotstein C.M.F., Betts R.F., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 (2007) 883-893
21. Rodriguez-Adrian L.J., King R.T., Tamayo-Derat L.G., Miller J.W., Garcia C.A., and Rex J.H. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore) 82 (2003) 187-202
22. Khan F.A., Slain D., and Khakoo R.A. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 27 (2007) 1711-1721
23. Sobel J.D., Bradshaw S.K., Lipka C.J., and Kartsonis N.A. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 44 (2007) e46-e49